

Information

Scientific Chair

Prof. Dr. Gabriela Riemekasten
Department of Rheumatology
University of Lübeck
E-Mail: gabriela.riemekasten@uksh.de



Scientific Coordinator

Alexander Hackel
E-Mail: alexandermaximilian.hackel@uksh.de

Call for Abstracts

Please submit your abstract and present your scientific work.
Submission Deadline: July 31, 2022
www.rab-symposium.org/submissions

Venue and Travel

Media Docks **Livestream - online participation**
Willy-Brandt-Allee 31 Login to the conference portal
23554 Lübeck, Germany www.rab-symposium.org/login

Please use the event ticket of Deutsche Bahn or Lübeck Air.
www.rab-symposium.org/venue-and-travel

Registration

Please register on the conference portal for submissions, tickets and other features. The fee for in-person participation includes a nominal fee. Online participation is free, but needs registrations as well.
www.rab-symposium.org/registration

Sponsors

We thank our sponsors for their support.
www.rab-symposium.org/support

 Infinite Science | Conferencing

www.rab-symposium.org

Committee



Prof. Dr. Gabriela Riemekasten
Lübeck, Germany



Prof. Dr. Yehuda Shoenfeld
Tel Aviv, Israel



Prof. Dr. Carmen Scheibenbogen
Berlin, Germany

Host and Organization

Infinite Science GmbH
Maria-Goeppert-Str. 1, 23562 Lübeck
info@rab-symposium.org | www.infinite-science.de



RAB-Symposium

Regulatory Autoantibodies Targeting GPCRs

September 15-16, 2022
Lübeck, Germany

With optional online participation

www.rab-symposium.org



DFG Deutsche
Forschungsgemeinschaft

Dear Sir or Madam, dear Colleagues,

It gives me great pleasure to announce the fourth hybrid symposium on regulatory autoantibodies targeting G protein-coupled receptors (GPCRs) in Lübeck.

GPCRs are involved in a variety of physiological and pathophysiological processes. So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and monoclonal antibodies for the treatment of cancer, infections, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic intervention. Therefore, the aim of this symposium is to bring together the current knowledge on the role of autoantibodies targeting GPCRs in various diseases, such as cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or systemic lupus erythematosus. In addition, one aim is to bring together the mode of action of autoantibodies in immune regulation and pathogenesis.

I hereby cordially invite you to participate in this stimulating symposium with outstanding speakers from the field of GPCR research and fruitful discussions as well as poster sessions. I look forward to welcoming you to the beautiful Hanseatic city of Lübeck and encourage you and your colleagues to contribute to this exciting meeting.



Welcome to the in-person symposium with the option to participate online.

Prof. Dr. Gabriela Riemekasten

Department of Rheumatology
University of Lübeck

OPENING

09:00 Welcome

PROVOCATIVE STATEMENTS

09:05 All diseases are autoimmune diseases · Y. Shoenfeld

09:35 All diseases are GPCR abs mediated diseases · G. Riemekasten

10:05 Coffee break

COVID-19 AND NATURAL REGULATORY ABS

10:30 Anti-GPCR and acute COVID infection · F. Tran

11:00 SARS-Cov-2 v accination and anti-GPCR abs · T. Lange

11:30 Role of GPCR abs in Post-COVID syndrome · C. Scheibenbogen

12:00 Lunch break

13:45 Poster Session

PROGRESS IN PRECLINICAL MODELS TO MEASURE RAB AB EFFECTS

14:30 Animal models · X. Yu

15:00 Modification of animal models and GPCR/monoclonal abs
F. Petersen

15:30 Stroke and anti-GPCR abs · M. Endres

16:00 Coffee break

ANTI-GPCR BINDING BIOLOGY

16:30 Glycocalix and their interplay with GPCR abs · K. Kusche-Viehrog

17:00 Ab binding by measuring the crystal structures of GPCRs
P. Scherer

17:30 Biology of regulatory abs, insight from bioinformatics
O. Cabral Marques

18:30 Get together, Networking in the industrial exhibition

NATURAL RAB-INDUCED SIGNALLING

09:00 Catalytic antibodies from psychoses condition · K. Sivasankaran

09:30 What comes after ab binding? How to go beyond the cell surface?
E. Kostenis

10:00 Signalling of GPCR abs in different cellular models · R. Catar

10:30 Ab-induced proteome · H. Grasshoff

11:00 Coffee break

THERAPY

11:30 Aptamer BQ007, a novel therapeutic agent? · B. Hohenberger

12:00 Interacting with GPCR by peptides · J. Bernhagen

12:30 Lunch and Postersession

FIBROMYALGIA AND ME/CSF AS ANOTHER CHALLENGE

14:00 Fibromyalgia: ab-mediated pathogenesis · C. I. Svensson

14:30 GPCR abs and influencing factors: Learning from a study on fibromyalgia syndrome · H. Graßhoff

15:00 Role of GPCR abs in chronic fatigue syndrome · F. Sotzny

15:30 Coffee break

NEW PATHOGENESIS INSIGHTS FROM SSC

16:00 GPCR abs in systemic sclerosis · S. Schinke

16:30 t.b.d.

17:00 GPCR abs and EVs in SSc - the bad boys affecting immune cell functions · A. Hackel

LECTURE

17:30 EVs and antibody-interactions · D. Pisetzky

WHAT ARE THE NEXT STEPS, HOW TO PROCEED?

18:15 General discussion